Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Atrial Fibrillation

In brief

The investigators hypothesize that ranolazine would decrease the incidence of recurrence of Atrial Fibrillation (AF) after electrical cardioversion of persistent AF. Patients with persistent AF who are candidates for electrical cardioversion will be randomized to either placebo or ranolazine after successful electrical cardioversion.

Key facts

Study ID
NCT01349491
Run by
University of Oklahoma
People needed
10
Starts
2012-03-01
Expected to finish
2014-06-01
Last updated by the study team
2017-04-27

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.